Regenxbio Q4 revenue rises but loss widens as costs increase

Reuters03-05
Regenxbio Q4 revenue rises but loss widens as costs increase

Overview

  • Biotech firm's Q4 revenue rose to $30.3 mln, driven by collaborations and royalties

  • Net loss for Q4 widened to $67.1 mln from $51.2 mln last year

  • Company advancing gene therapy pipeline with key milestones expected in 2026

Outlook

  • Regenxbio expects RGX-202 topline data in early Q2 2026

  • Company anticipates sura-vec wet AMD pivotal data in Q4 2026

  • Regenxbio forecasts cash to fund operations into early 2027

Result Drivers

  • COLLABORATIONS AND ROYALTIES - Revenue increase driven by collaborations and royalty monetization

  • RESEARCH AND DEVELOPMENT EXPENSES - Increased R&D expenses due to RGX-202 pivotal trials and manufacturing costs

  • PIPELINE ADVANCEMENT - Advancing gene therapy pipeline with key milestones expected in 2026

Company press release: ID:nPn7V2N5Va

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 License & Royalty Revenue

$27.15 mln

Q4 Net Income

-$67.15 mln

Q4 Operating Expenses

$87.97 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Regenxbio Inc is $29.00, about 217.3% above its March 4 closing price of $9.14

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment